SPATA17-AS1

Across TCGA pan-cancer cohorts, SPATA17-AS1 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SPATA17-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SPATA17-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPATA17-AS1 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

HNSC, BRCA, and THCA are the cancer types where SPATA17-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPATA17-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	+0.030	.020	6	view →
BRCA	All	All	+0.112	.012	4	view →
THCA	All	All	−0.108	.006	4	view →
CHOL	All	II,III,IV	+0.755	<.001	3	view →
BLCA	Female	III,IV	+0.145	.003	3	view →
PAAD	Male	All	+0.280	.019	2	view →
KIRC	All	All	−0.040	.013	2	view →
STAD	All	All	+0.036	.026	2	view →
LUAD	All	All	+0.156	.015	1	view →
KIRP	Male	All	−0.070	.038	1	view →
COAD	Male	All	+0.048	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SPATA17-AS1–HNSC

Open the HNSC breakdown →